QSI Quantum-Si Incorporated Class ABATS:QSICrypto-CrapshootsAnalyst Consensus BUY 1SB / 4B / 2H / 0S / 0SS Bottom Line: The computed scores are mediocre across the board—overall 51, valuation 50, financial 53, growth 50—reflecting a company in deep distress with collapsing revenue and extreme cash burn. The 'BUY' analyst consensus and consecutive earnings beats provide some counterbalance, but the -46% revenue decline and -6,212% operating margin are existential red flags. This is a high-risk, high-volatility speculative bet (beta 3.20) on a turnaround that has yet to materialize. Risk/reward may favor aggressive investors at this depressed valuation only if management can demonstrate imminent revenue stabilization, but the current trajectory suggests significant downside remains if fundamentals don't improve rapidly. ↑ Catalysts Recent earnings have consistently beaten analyst estimates, with Q1 2026 delivering a 9.99% surprise and Q4 2025 a 35.79% surprise, indicating operational improvements and better-than-expected cost management despite challenging revenue conditions. The company operates with zero debt (0 debt-to-equity), providing significant financial flexibility to fund product development and commercialization initiatives without dilution pressure or interest burden during this capital-intensive growth phase. Analyst consensus remains a 'BUY' despite recent operational challenges, suggesting the Street sees value in the current $270M market cap relative to the company's life sciences tools platform and technology potential. At $1.22 per share, the stock is trading significantly below its 52-week high of $3.10, offering substantial upside if the company can stabilize revenue trends and demonstrate product-market fit in its next-generation sequencing platform. ↓ Risks Revenue declined 46.21% on a trailing twelve-month basis, signaling severe demand issues, customer adoption challenges, or competitive displacement in what should be a growing life sciences tools market. Operating margin of -6,211.66% is catastrophic, indicating the company is burning through cash at an unsustainable rate relative to its minimal revenue base, raising serious going-concern questions without a clear path to profitability. Return on equity of -47.35% demonstrates the company is destroying shareholder capital at an alarming pace, with no P/E ratio available due to deeply negative earnings. Extreme beta of 3.20 means the stock exhibits more than three times the volatility of the broader market, making it unsuitable for risk-averse investors and subject to violent downside moves in any market correction.